IP Library Granted Patent US 12,709,669
Granted Patent B2
US 12,709,669 · App. 17/581,615 · Granted Aug 18, 2026

Polymeric surface having reduced biomolecule adhesion to thermoplastic articles of such substrate

Inventors: Ahmad Taha (Auburn, AL); John T. Felts (Alameda, CA)
Assignee: SIO2 MEDICAL PRODUCTS, INC.
C08J7/123B01L3/5085B01L3/50855C08J7/0427C08J7/048C08J7/056C08J7/06C23C16/50B01L2300/0829B01L2300/16C08J7/18C08J2300/22C08J2323/12C08J2325/02C08J2471/02C08J2483/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,709,669
App. No.
17/581,615
Filed
Jan 21, 2022
Granted
Aug 18, 2026
Kind
B2
Art Unit
1767
USPC
428/420
Abstract

A substrate is described having a treated contact surface comprising a carbon or silicon compound comprising from 1 to 30 atomic percent oxygen, from 0.1 to 30 atomic percent nitrogen, or both, each as measured by XPS. The treated contact surface has a biomolecule recovery percentage greater than the biomolecule recovery percentage of the surface before treatment according to the method.

Claims (27)

1 . A method for providing a non-specific biomolecule adsorption and/or non-specific biomolecule binding resistant coated surface, the method comprising the steps:

(a) providing a substrate with a prepared surface;

(b) reacting the prepared surface with at least one zwitterionic copolymer, thus forming a non-specific biomolecule adsorption and/or biomolecule binding resistant coated surface;

wherein reacting the prepared surface with at least one zwitterionic copolymer comprises:

reacting the prepared surface with a vapor comprising at least one silyl amine coupling agent to provide an amine modified surface;

contacting the amine modified surface with a copolymer solution comprising a solvent, wherein the copolymer comprises at least one copolymerizable zwitterionic monomer and at least one copolymerizable epoxy monomer, optionally in the presence of a polymerization initiator; and

wherein the at least one copolymerizable epoxy monomer is selected from the group consisting of (E)-(oxiran-2-yl)methyl but-2-enoate, (3,3-dimethyloxiran-2-yl)methyl methacrylate, (E)-(oxiran-2-yl)methyl cinnamate, (oxiran-2-yl)methyl 2-methylenebutanoate, 1-(oxiran-2-yl) propyl acrylate, 1-(oxiran-2-yl)ethyl methacrylate, (oxiran-2-yl)methyl 3-methyl-2-methylenebutanoate, (oxiran-2-yl)methyl 2-methylenepentanoate, (3-methyloxiran-2-yl)methyl acrylate, 2-(oxiran-2-yl) propan-2-yl acrylate, (oxiran-2-yl)methyl 2-methylenehexanoate, (3-methyloxiran-2-yl)methyl methacrylate, (3,3-dimethyloxiran-2-yl)methyl acrylate, and combinations thereof.

2 . The method of claim 1 , wherein providing the substrate with the prepared surface comprises:

(i) providing a substrate in a reaction chamber;

(ii) drawing a vacuum in the reaction chamber;

(iii) providing a gas comprising O 2 or an organosilicon precursor and optionally O 2 in the vicinity of the substrate surface; and

(iv) generating a plasma from the gas, thus forming the prepared substrate surface.

3 . The method of claim 1 , wherein the at least one silyl amine coupling agent is selected from the group consisting of 3-aminopropyltriethoxysilane, 3-aminopropyltrimethoxysilane, 4-aminobutyltriethoxysilane, m-aminophenyltrimethoxysilane, p-aminophenyltrimethoxysilane, o-aminophenyltrimethoxysilane, 3-aminopropyltris(methoxyethoxyethoxy) silane, 11-aminoundecyltriethoxysilane, 3-(m-aminophenoxy) propyltrimethoxysilane, aminopropylsilanetriol, 3-aminopropylmethyldiethoxysilane, 3-aminopropyl-diisopropylethoxysilane, 3-aminopropyldimethylethoxysilane, N-(2-aminoethyl)-3-aminopropyltrimethoxysilane, N-[3-(trimethoxysilyl) propyl]ethylenediamine, N-(2-aminoethyl)-3-aminopropyltriethoxysilane, N-(6-aminohexyl)aminomethyltriethoxysilane, N-(6-aminohexyl)aminopropyltrimethoxysilane, N-(2-aminoethyl)-11-aminoundecyltrimethoxysilane, (aminoethylaminomethyl) phenethyltrimethoxysilane, N-3-[(amino (polypropylenoxy)]aminopropyltrimethoxysilane, N-(2-aminoethyl)-3-aminopropylsilanetriol, N-(2-aminoethyl)-3-aminopropylmethyldimethoxysilane, N-(2-aminoethyl)-3-aminoisobutylmethyldimethoxysilane, (aminoethylamino)-3-isobutyldimethylmethoxysilane, (3-trimethoxysilylpropyl) diethylenetriamine, N-butylaminopropyltrimethoxysilane, N-ethylaminoisobutyltrimethoxysilane, N-methylaminopropyltrimethoxysilane, N-phenylaminopropyltrimethoxysilane, 3-(N-allylamino) propyltrimethoxysilane, (cyclohexylaminomethyl)triethoxysilane, N-cyclohexylaminopropyltrimethoxysilane, N-ethylaminoisobutylmethyldiethoxysilane, (phenylaminomethyl)methyldimethoxysilane, N-phenylaminomethyltriethoxysilane, N-methylaminopropylmethyldimethoxysilane, bis(2-hydroxyethyl)-3-aminopropyltriethoxysilane, 3-(N-styrylmethyl-2-aminoethylamino)-propyltrimethoxysilane hydrochloride, (2-N-benzylaminoethyl)-3-aminopropyl-trimethoxysilane, bis(triethoxysilylpropyl)amine, bis(trimethoxysilylpropyl)amine, bis[(3-trimethoxysilyl) propyl]-ethylenediamine, bis[(3-trimethoxysilyl) propyl]-ethylenediamine, bis(methyldiethoxysilylpropyl)amine, N-allyl-aza-2,2-dimethoxysilacyclopentane, N-aminoethyl-aza-2,2,4-trimethyl-silacyclopentane, N-(3-aminopropyldimethylsila) aza-2,2-dimethyl-2-silacyclopentane, N—N-butyl-aza-2,2-dimethoxysilacyclopentane, 2,2-dimethoxy-1,6-diaza-2-silacyclooctane, N-methyl-aza-2,2,4-trimethylsilacylcopentane, 1-(N—(N′,N′-dimethylaminoethyl))-1-aza-2,2,4-trimethyl-2-silacyclopentane, and combinations thereof.

4 . The method of claim 1 , wherein the at least one copolymerizable zwitterionic monomer is selected from the group consisting of 2-(meth)acryloyloxyethyl-2′-(trimethylammonio)ethyl phosphate; 2-(methacryloxy)ethyl 2-(diimethylammonio)ethyl phosphate; 2-(methacryloxy)ethyl-2-(dimethylammonio)ethylcarboxylate; 2-(methacryloxy)ethyl-2-(dimethylammonio) propylsulfonate; 2-(methyacrylamido)ethyl-2-(dimethylammonio)-propylsulfonate; phosphoric acid 2-(methacryloyloxy)ethyl 2-(trimethylammonio)ethyl ester); 3-(meth)acryloyloxypropyl-2′-(trimethylammonio)ethyl phosphate, 4-(meth)acryloyloxybutyl-2′-(trimethylammonio)ethyl phosphate, 5-(meth)acryloyloxypentyl-2′-(trimethylammonio)ethyl phosphate, 6-(meth)acryloyloxyhexyl-2′-(trimethylammonio)ethyl phosphate, 2-(meth)acryloyloxyethyl-2′-(trimethylammonio)ethyl phosphate, 2-(meth)acryloyloxyethyl-2′-(tripropylammonio)ethyl phosphate, 2-(meth)acryloyloxyethyl-2′-(tributylammonio)ethyl phosphate, 2-(meth)acryloyloxypropyl-2′-(trimethylammonio)ethyl phosphate, 2-(meth)acryloyloxybutyl-2′-(trimethylammonio)ethyl phosphate, 2-(meth)acryloyloxypentyl-2′-(trimethylammonio)ethyl phosphate, 2-(meth)acryloyloxyhexyl-2′-(trimethylammonio)ethyl phosphate, 2-(meth)acryloyloxyethyl-3′-(trimethylammonio) propyl phosphate, 3-(meth)acryloyloxypropyl-3′-(trimethylammonio) propyl phosphate, 4-(meth)acryloyloxybutyl-3′-(trimethylammonio) propyl phosphate, 5-(meth)acryloyloxypentyl-3′-(trimethylammonio)-propyl phosphate, 6-(meth)acryloyloxyhexyl-3′-(trimethylammonio) propyl phosphate, 2-(meth)acryloyloxyethyl-4′-(trimethylammonio)butyl phosphate, 3-(meth)acryloyloxypropyl-4′-(trimethylammonio)butyl phosphate, 4-(meth)acryloyloxybutyl-4′-(trimethylammonio)butyl phosphate, 5-(meth)acryloyloxypentyl-4′-(trimethylammonio)butyl phosphate, 6-(meth)acryloyloxyhexyl-4′-(trimethylammonio)butyl phosphate, 2-(vinyloxy)ethyl-2′-(trimethylammonio)ethyl phosphate, 2-(allyloxy)ethyl-2′-(trimethylammonio)ethyl phosphate, 2-(p-vinylbenzyloxy)ethyl-2′-(trimethylammonio)ethyl phosphate, 2-(p-vinylbenzoyloxy)ethyl-2′-(trimethylammonio)ethyl phosphate, 2-(styryloxy)ethyl-2′-(trimethylammonio)ethyl phosphate, 2-(p-vinylbenzyl)ethyl-2′-(trimethylammonio)ethyl phosphate, 2-(vinyloxycarbonyl)ethyl-2′-(trimethylammonio)ethyl phosphate, 2-(allyloxycarbonyl)ethyl-2′-(trimethylammonio)ethyl phosphate, 2-(acryloylamino)ethyl-2′-(trimethylammonio)ethyl phosphate, 2-(vinylcarbonylamino)ethyl-2′-(trimethylammonio)ethyl phosphate, 2-(allyloxycarbonylamino)ethyl-2′-(trimethylammonio)ethyl phosphate, 2-(butyroyloxy)ethyl-2′-(trimethylammonio)ethyl phosphate, 2-(crotonoyloxy)ethyl-2′-(trimethylammonio)ethyl phosphate, ethyl-(2′-trimethylammonioethylphosphorylethyl) fumarate, butyl-(2′-trimethylammonio-ethylphosphorylethyl) fumarate, hydroxyethyl-(2′-trimethylammonioethyl-phosphorylethyl) fumarate, β-carboxyethyl-3,3-dimethyammoniumethylmethacrylate, sulfopropyl-3,3-dimethylammoniumethylmethacrylate, and combinations thereof.

5 . The method of claim 1 , wherein the solvent is selected from the group consisting of water, methanol, ethanol, isopropanol, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethylsulfoxide, methylene chloride, 1,2-dicholorethane, and combinations thereof.

6 . The method of claim 1 , wherein the substrate is a polymer.

7 . The method of claim 6 , wherein the polymer is selected from the group consisting of an olefin polymer; polypropylene (PP); polyethylene (PE); cyclic olefin copolymer (COC); cyclic olefin polymer (COP); polymethylpentene; polyester; polyethylene terephthalate; polyethylene naphthalate; polybutylene terephthalate (PBT); PVdC (polyvinylidene chloride); polyvinyl chloride (PVC); polycarbonate; polymethylmethacrylate; polylactic acid; polylactic acid; polystyrene; hydrogenated polystyrene; poly(cyclohexylethylene) (PCHE); epoxy resin; nylon; polyurethane polyacrylonitrile; polyacrylonitrile (PAN); and an ionomeric resin.

8 . The method of claim 1 , wherein the non-specific biomolecule adsorption and/or non-specific binding resistant coated surface has decreased binding of biomolecules compared to a non-treated substrate.

9 . The method of claim 8 , wherein the biomolecules are selected from the group consisting of nucleotides, amino acids, sugars, fatty acids, nucleic acid molecules, polypeptides, polynucleotides, polysaccharides, lipids, steroids, glycoproteins, lipoproteins, glycolipids, DNA, DNA-protein conjugates, RNA, RNA-conjugates, antibodies, and receptors, receptor fusion constructs, receptor fusion proteins, chimeric proteins, antibody fusion constructs, and antibody fusion proteins.

10 . The method of claim 1 , wherein the substrate is a surface of a vessel.

11 . The method of claim 10 , wherein the vessel is selected from the group consisting of a microplate; a centrifuge tube; a pipette tip; a cuvette, a microwell plate; an ELISA plate; a microtiter plate; a 96-well plate; a 384-well plate; a 1536-well plate; a round bottom flask; and an Erlenmeyer flask.

12 . The method of claim 10 , wherein the substrate is the interior surface of a vessel.

13 . The method of claim 12 , wherein the vessel is a vial, a syringe, or a cartridge.

14 . The method of claim 13 , wherein the interior surface comprises a coating or layer of PECVD deposited SiOxCyHz or SiNxCyHz, in which x is from about 0.5 to about 2.4 as measured by x-ray photoelectron spectroscopy (XPS), y is from about 0.6 to about 3 as measured by XPS, and z is from about 2 to about 9 as measured by Rutherford backscattering spectrometry (RBS).

15 . The method of claim 13 , wherein the interior surface comprises a barrier coating or layer of SiOx, in which x is from about 1.5 to about 2.9 as measured by x-ray photoelectron spectroscopy (XPS).

16 . A product comprising a non-specific biomolecule adsorption and/or non-specific biomolecule binding resistant coated surface prepared by the method according to claim 1 .

17 . The product of claim 16 , wherein the product is a vessel, and wherein at least a portion of an interior surface of the vessel comprises the non-specific biomolecule adsorption and/or non-specific biomolecule binding resistant coated surface.

Assignments (6)
SECURITY INTEREST Recorded Sep 5, 2024
From: SIO2 MEDICAL PRODUCTS, LLC
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 068849/0489 →
CHANGE OF NAME Recorded Sep 4, 2024
From: SIO2 MEDICAL PRODUCTS, INC.
To: SIO2 MEDICAL PRODUCTS, LLC
Reel/Frame 068839/0691 →
SECURITY INTEREST Recorded Aug 9, 2023
From: SIO2 MEDICAL PRODUCTS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 064544/0940 →
SECURITY INTEREST Recorded Dec 9, 2022
From: SIO2 MEDICAL PRODUCTS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 062045/0380 →
SECURITY INTEREST Recorded Dec 7, 2022
From: SIO2 MEDICAL PRODUCTS, INC.
To: SALZUFER HOLDING INC., AS ADMINISTRATIVE AGENT
Reel/Frame 062094/0121 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2022
From: TAHA, AHMAD; FELTS, JOHN T.
To: SIO2 MEDICAL PRODUCTS, INC.
Reel/Frame 059498/0454 →
Continuity (6)
Continuation 15776728 · Jun 15, 2016
Provisional Application 62320246 · Apr 8, 2016
Provisional Application 62257266 · Nov 19, 2015
Provisional Application 62257269 · Nov 19, 2015
Provisional Application 62255555 · Nov 16, 2015
Related Publication 20220227954A1 · Jul 21, 2022
References Cited (44)
US 4261806A · Asai et al. · 1981 [cited by applicant]
US 4948628A · Montgomery et al. · 1990 [cited by applicant]
US 5147678A · Foerch et al. · 1992 [cited by applicant]
US 5344462A · Paskalov et al. · 1994 [cited by applicant]
US 5376413A · Callebert et al. · 1994 [cited by applicant]
US 6082292A · Denes et al. · 2000 [cited by applicant]
US 6090901A · Bowers · 2000 [cited by examiner]
US 8962097B1 · Yokley et al. · 2015 [cited by applicant]
US 20040062882A1 · Liebmann-Vinson · 2004 [cited by applicant]
US 20100072642A1 · Broad · 2010 [cited by examiner]
US 20110110894A1 · Drahos et al. · 2011 [cited by applicant]
US 20110116992A1 · North et al. · 2011 [cited by applicant]
US 20110305881A1 · Schultz · 2011 [cited by examiner]
US 20120058635A1 · Tsuji · 2012 [cited by applicant]
US 20120237555A1 · Williams · 2012 [cited by examiner]
US 20130022752A1 · Antonakas · 2013 [cited by applicant]
US 20130158211A1 · Zhang · 2013 [cited by examiner]
US 20130197451A1 · Ishii · 2013 [cited by examiner]
US 20130291632A1 · Felts et al. · 2013 [cited by applicant]
US 20140004022A1 · Sagona · 2014 [cited by examiner]
US 20180334545A1 · Taha · 2018 [cited by applicant]
CN 102459693A · 2012 [cited by applicant]
CN 103080197A · 2013 [cited by applicant]
CN 108463493 · 2018 [cited by applicant]
DE 10066431 · 2013 [cited by applicant]
EP 1859866 · 2007 [cited by applicant]
EP 1892080 · 2008 [cited by applicant]
EP 2251452 · 2010 [cited by applicant]
EP 2572861A1 · 2013 [cited by applicant]
JP 59215328A · 1984 [cited by applicant]
JP 2013237812A · 2013 [cited by applicant]
WO 200069548 · 2000 [cited by applicant]
WO 2010132591 · 2010 [cited by applicant]
WO 2013041312 · 2013 [cited by applicant]
China National Intellectual Property Administration, Notification of the First Office Action, Application No. 201680062146.6, dated Aug. 26, 2020 (19 pages). [cited by applicant]
Vandencasteele et al. “Plasma-modified Polymer Surfaces: Characterization using XPS”, Journal of Electron Spectroscopy and Related Phenomena 2010, 178-179,394-408. (Year: 2010). [cited by applicant]
Yasuda, “Modification of Polymer Surfaces by Plasma Treatment and Plasma Polymerization”; Lee; Polymer Wear and Its Control; ACS Symposium Series; American Chemical Society; Washington, DC 1985, 89-102. (Year: 1985). [cited by applicant]
PCT, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration application No. PCTIUS2016/037674 dated Sep. 30, 2016 (14 pages). [cited by applicant]
Spierings et al: “Water absorption and the effects of moisture on the dynamic properties of synthetic mountaineering ropes”, International Journal of Impact Engineering, Pergamon, GB, vol. 34, No. 2, Nov. 17, 2006 (Nov.… [cited by applicant]
J.V. Da Maia et al: “Influence of gas and 1-12, treatment time on the surface modification of EPDM rubber treated a afterglow microwave plasmas”, Applied Surface Science, vol. 285, Nov. 1, 2013 (Nov. 1, 2013), pp. 918-9… [cited by applicant]
Midwoud et al. “Comparison of Biocompatibility and Adsorption Properties of Different Plastics for Advanced Microfluidic Cell and Tissue Culture Models”, Anal. Chem., 2012,84,3938-3944 (Year: 2012). [cited by applicant]
Ghasemi et al. “Ammonia Plasma Treated Polyethylene Films for Adsorption or Covalent Immobilization of Trypsin: Quantitative Correlation between X-ray Photoelectron Spectroscopy Data and Enzyme Activity”, J. Phys. Chem.… [cited by applicant]
Extended European Search Report for Application No. 20215505.7, dated Mar. 16, 2022, 13 pages. [cited by applicant]
Korean Office Action for Application No. 10-2017-7030749, issued Sep. 26, 2023, 13 pages. [cited by applicant]